Valion Bio posts Q1 net loss of $6.2M; cash falls to $7.2M; advances Entolimod

Valion Bio, Inc.

Net loss $6.2M ($2.23/share) vs $1.5M ($2.52/share) a year ago; operating expenses $5.6M (was $1.4M).
Cash and equivalents $7.2M at March 31, 2026, down from $12.6M at Dec 31, 2025.
Government engagement broadened with BARDA, NIAID, and Dept of War for Entolimod as ARS countermeasure.
Velocity Bioworks CDMO integration advancing; facility supports internal and third-party biologics manufacturing.
Pipeline includes Entolimod (Animal Rule pathway) and Entolasta (TLR5 agonist for oncology supportive care).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Valion Bio, Inc. reported financial results for the three months ended March 31, 2026.

Period: the three months ended March 31, 2026
Result: reported results

Exact text from the filing

Valion Bio Reports First Quarter 2026 Financial Results

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-017082

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.